We are live on ! Find out more
MLICM

Metropolitan Life Insurance Company (MetLife) Portfolio holdings

AUM $328M
1-Year Est. Return 9.77%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+9.77%
3 Year Est. Return
+50.33%
5 Year Est. Return
+74.21%
10 Year Est. Return
+345.05%
AUM
$7.36B
AUM Growth
+$457M
Cap. Flow
-$178M
Cap. Flow %
-2.42%
Top 10 Hldgs %
26.1%
Holding
2,906
New
66
Increased
422
Reduced
1,573
Closed
124

Sector Composition

Rank Sector Weight
1 Technology 25.69%
2 Consumer Discretionary 12.47%
3 Healthcare 12.1%
4 Financials 11.43%
5 Communication Services 8.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EWCZ
2476
DELISTED
European Wax Center
EWCZ
$100K ﹤0.01%
3,309
FCNCA icon
2477
First Citizens BancShares
FCNCA
$25.6B
$100K ﹤0.01%
121
+1
+0.8% +$834
TLYS icon
2478
Tilly's
TLYS
$122M
$100K ﹤0.01%
6,227
+2,653
+74% +$40K
ALTO icon
2479
Alto Ingredients
ALTO
$326M
$100K ﹤0.01%
20,852
ANNX icon
2480
Annexon
ANNX
$862M
$100K ﹤0.01%
8,725
RBB icon
2481
RBB Bancorp
RBB
$466M
$100K ﹤0.01%
3,826
-1,747
-31% -$44.6K
TBCH
2482
Turtle Beach Corp
TBCH
$230M
$100K ﹤0.01%
4,502
BSRR icon
2483
Sierra Bancorp
BSRR
$532M
$99.9K ﹤0.01%
3,681
+1,068
+41% +$27.6K
BWB icon
2484
Bridgewater Bancshares
BWB
$620M
$99.9K ﹤0.01%
5,649
PINC
2485
DELISTED
Premier
PINC
$99.8K ﹤0.01%
2,425
+6
+0.2% +$237
FUTU icon
2486
Futu Holdings
FUTU
$14.7B
$99.6K ﹤0.01%
2,300
ORGO icon
2487
Organogenesis Holdings
ORGO
$226M
$99.5K ﹤0.01%
10,766
-514
-5% -$5.46K
BTAI icon
2488
BioXcel Therapeutics
BTAI
$34.9M
$99.3K ﹤0.01%
305
NPK icon
2489
National Presto Industries
NPK
$987M
$99.2K ﹤0.01%
1,209
-528
-30% -$44.3K
APEI icon
2490
American Public Education
APEI
$828M
$99.1K ﹤0.01%
4,454
FRPH icon
2491
FRP Holdings
FRPH
$425M
$99.1K ﹤0.01%
3,428
DXPE icon
2492
DXP Enterprises
DXPE
$3B
$98.9K ﹤0.01%
3,853
-1,696
-31% -$51.6K
PLRX icon
2493
Pliant Therapeutics
PLRX
$66.9M
$98.7K ﹤0.01%
7,310
AVAH icon
2494
Aveanna Healthcare
AVAH
$2.46B
$98.6K ﹤0.01%
13,327
+5,632
+73% +$40.9K
ERAS icon
2495
Erasca
ERAS
$6.25B
$98.5K ﹤0.01%
6,325
CUE icon
2496
Cue Biopharma
CUE
$131M
$98.1K ﹤0.01%
289
-14
-5% -$5.41K
NGMS
2497
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
$97.8K ﹤0.01%
+3,522
New +$122K
UTMD icon
2498
Utah Medical Products
UTMD
$230M
$97.8K ﹤0.01%
978
CIVB icon
2499
Civista Bancshares
CIVB
$595M
$97.7K ﹤0.01%
4,004
AFCG
2500
AFC Gamma
AFCG
$68.7M
$97.5K ﹤0.01%
+6,262
New +$97.5K

Similar funds

Metropolitan Life Insurance Company (MetLife)'s Q4 2021 Portfolio in Review

As of Q4 2021, Metropolitan Life Insurance Company (MetLife) held 2,906 positions worth $7.36B, up 6.6% from $6.9B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Metropolitan Life Insurance Company (MetLife)'s Q4 2021 filing shows 66 new, 422 increased, 1,573 reduced and 124 closed positions. Its largest new stake was Kyndryl: 32,951 shares worth $596K. The largest sale was iShares Russell 1000 Growth ETF, an estimated $18.3M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Metropolitan Life Insurance Company (MetLife)'s largest Q4 2021 buy was Kyndryl: 32,951 shares worth $596K.
  • Metropolitan Life Insurance Company (MetLife) added most to State Street SPDR S&P 500 ETF Trust in Q4 2021, an estimated $34.8M increase.
  • Metropolitan Life Insurance Company (MetLife)'s biggest Q4 2021 reduction was iShares Russell 1000 Growth ETF, cutting an estimated $18.3M.
  • Metropolitan Life Insurance Company (MetLife) fully exited Kansas City Southern in Q4 2021, selling an estimated $3.18M.
  • Metropolitan Life Insurance Company (MetLife)'s ten largest holdings make up 26% of its $7.36B portfolio in Q4 2021.
  • Metropolitan Life Insurance Company (MetLife) opened 66 new positions and closed 124 in Q4 2021.
  • Metropolitan Life Insurance Company (MetLife)'s portfolio value rose 6.6% quarter-over-quarter to $7.36B.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.